JP2004097033A - Method for producing placental extract - Google Patents

Method for producing placental extract Download PDF

Info

Publication number
JP2004097033A
JP2004097033A JP2002260495A JP2002260495A JP2004097033A JP 2004097033 A JP2004097033 A JP 2004097033A JP 2002260495 A JP2002260495 A JP 2002260495A JP 2002260495 A JP2002260495 A JP 2002260495A JP 2004097033 A JP2004097033 A JP 2004097033A
Authority
JP
Japan
Prior art keywords
protease
placenta
digestion
enzyme
raw material
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002260495A
Other languages
Japanese (ja)
Inventor
Eiji Kimoto
木本 英治
Koichiro Hiroya
広谷 光一郎
Hideo Usugane
薄金 英雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HOWAIZU KK
NIPPON SEIBUTSU SEIZAI KK
SANKYO RIKA KOGYO KK
Original Assignee
HOWAIZU KK
NIPPON SEIBUTSU SEIZAI KK
SANKYO RIKA KOGYO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HOWAIZU KK, NIPPON SEIBUTSU SEIZAI KK, SANKYO RIKA KOGYO KK filed Critical HOWAIZU KK
Priority to JP2002260495A priority Critical patent/JP2004097033A/en
Publication of JP2004097033A publication Critical patent/JP2004097033A/en
Pending legal-status Critical Current

Links

Abstract

<P>PROBLEM TO BE SOLVED: To provide a method for producing a placental extract by which complicatedness of treatment such as regulation of proper action pH in an enzyme digesting process in a conventional method for extraction, removal of hydrochloric acid after completing digestion and final correction of the pH as the placental extract is eliminated. <P>SOLUTION: The complicatedness in an enzyme digesting process, i.e. the complicatedness of the treatment such as the regulation of the proper action pH in the enzyme digesting process, removal of the hydrochloric acid after completing the digestion and final correction of the pH as the placental extract can be simplified by using a specific thermostable neutral proteolytic enzyme. Thereby, effective digestion can be carried out. <P>COPYRIGHT: (C)2004,JPO

Description

【0001】
【産業上の利用分野】
本発明はプラセンタエキスの製造方法に関し、詳しくは、ヒトまたはブタの正常分娩胎盤の耐熱性中性タン白質分解酵素消化によるプラセンタエキスの製造方法に関する。
【0002】
【従来の技術】
一般に哺乳動物の胎盤の生理機能は母体内での胎児の発育のための酸素の供給と栄養補給である。母体と胎児の循環系は栄養芽細胞層を介して完全に分離されている。過去10数年間に神経成長因子や肝細胞成長因子などの栄養因子が医学領域で注目され、これらの既知栄養因子のほとんどが胎盤栄養芽細胞で作り出されていることがわかった。
【0003】
プラセンタエキスは胎盤組織内に含まれているあらゆる成分が含まれるよう抽出されたもので、その生物活性は単一物質によるものでなく、各種の成分が多様に作用し、結合織増殖作用、抗老化作用、抗慢性潰瘍作用のほか、神経症状を主とする疾患、婦人科的疾患、皮フ科的疾患などに対する医療効果が既に人胎盤抽出エキスの注射薬などにより明らかとなっている。また、近年、これらの生物活性の中心となっているのは胎盤の栄養芽細胞が作り出す数々の栄養因子であることが明らかになりつつある。
【0004】
プラセンタエキスの望ましい有効成分としては、ヌクレオチド・ヌクレオシド、
遊離のアルギニンおよびアルギニンを含むペプチド、ステロイドホルモンの中間代謝物・特にC−21ステロイドおよびC−19ステロイド、ムコ多糖(ヒアルロン酸、コンドロイチン硫酸)、イノシトールおよびイノシトールリン脂質などが注目される。
【0005】
我が国において、投与剤プラセンタエキスとしては、満期正常分娩の人胎盤の塩酸による加熱加水分解液、及びペプシン消化液と残渣の塩酸加水分解液とを配合した薬品名「ラエンネック」の2種類がある。いずれの製造法も1950〜1960年代に開発されたもので、「ラエンネック」は1958年、適応症「肝硬変症」で厚生省(貌厚生労働省)より製造承認を受け、1984年、適応症拡大により「慢性肝疾患における肝機能の改善」の薬効再評価が公示された。
【0006】
プラセンタエキスは、具体的には、通常以下の手順で製造されている。
まず、ヒトまたはブタの正常分娩胎盤を2〜4℃で約4日間冷蔵し、洗浄、細挫してアセトンを加えてホモゲナイズし、脱脂、乾燥する。乾燥物を塩酸酸性(pH2.0)にし、ペプシンで一昼夜消化し、遠心分離して消化液を採取する。沈殿物は塩酸(5N)を加えて加熱し、加水分解する。加水分解液は活性炭で脱色し、濾過し、ペプシン消化液と混ぜ、陰イオン交換樹脂で塩酸を可及的に除去し、苛性ソーダーを用いてPH6.1〜6.4に補正し、プラセンタエキスとする。
【0007】
このプラセンタエキスはニンヒドリン試液で紫色、ビューレット反応で赤紫色〜青紫色に呈色する。有効成分の相対的含有量は窒素定量法(ケルダール法)で行い0.30〜0.35w/v%、強熱残分は1.0%以下である。
【0008】
また、別の方法では、検疫された妊娠3ケ月の健常ブタの新鮮胎盤を熱処理や化学処理を行うことなく、低温下で凍結、浸漬をくり返して、細胞組織を破砕し、そのプロトプラズマを抽出し、除タン白、限外漏過して調製しプラセンタリキッドとする。このプラセンタリキッドは100mlあたりアルカリ性ホスフアターゼ含量が1.00キング・アームストロング単位である。(アルカリ性ホスフアターゼを含む溶液100mlあたり、酵素反応で15分間に遊離するフェノールが1mgのときアルカリ性ホスフアターゼの力価が1キングアームストロング単位(1KAU)である。)
【0009】
プラセンタリキッドはニンヒドリン試液で紫色、ビューレット反応で赤紫色〜青紫色に呈色する。有効成分の相対的含有量は窒素定量法(ケルダール法)で行い0.30〜0.35w/v%、強熱残分は1.0%以下である。
【0010】
しかしながら、塩酸による加熱加水分解では、ヌクレチド・ヌクレオシドは核酸塩基にまで加水分解され、ムコ多糖の構成糖、イノシトールリン脂質などはほとんどが分解されてしまい、大量の黒褐色物質が産出されて栄養因子の減損をまねいている。また、着色物質の除去には活性炭による脱色が必要となり、甚だ煩雑である。
【0011】
塩酸酸性(pH2.0)、37℃でのペプシン消化では、栄養因子の大部分は分解されてしまう。しかし、いずれの製造法においても、塩酸を用いるため、陰イオン交換樹脂による塩酸の可及的除去、苛性ソーダー液によるPHの適正な中性化を必要とする。さらに、胎盤の中に比較的大量に含まれる過酸化脂質や胎盤臭の除去に活性炭を用いているが、不十分であり、有効な栄養因子の減損の役割が大きい。
【0012】
【発明が解決しようとする課題】
上述のような従来の抽出方法におけるような酵素消化過程に於ける適正作用PHの調整、消化完了後の塩酸の除去およびプラセンタエキスとしてのPHの最終補正など、処理の繁雑さを解消するプラセンタエキスの製造方法が望まれていた。
【0013】
【課題を解決するための手段】
本発明者らは、特定の耐熱性中性タン白質分解酵素を使用することにより、酵素消化過程における煩雑さ、すなわち、酵素消化過捏に於ける適正作用PHの調整、消化完了後の塩酸の除去およびプラセンタエキスとしてのPHの最終補正などの処理の繁雑さを簡素化することが可能となり、また有効な消化ができることを見出した。
【0014】
本発明は、正常分娩ヒトまたはブタ胎盤を、プロテアーゼーS、パパインW−40、プロテアーゼーNまたはプロテアーゼーPより選ばれる耐熱性中性タン白質分解酵素を使用して酵素消化することを特徴とするプラセンタエキスの製造方法であり、
また、この際、プロテアーゼーS、パパインW−40、プロテアーゼーNまたはプロテアーゼーPより選ばれる複数種の耐熱性中性タン白質分解酵素を使用して酵素消化することを特徴とするプラセンタエキスの製造方法であり、
また、この酵素消化を撹拌下、温度25〜65℃で行うことを特徴とするプラセンタエキスの製造方法である。
【0015】
【発明の実施の形態】
ヒトまたはブタの正常分娩により娩出される胎盤を使用する。胎盤は、通常、変性、アポトーシス、懐死などの退行性変化を伴っており、血液を含む離漿および黒褐色血餅を水道水で洗浄しながら充分に除去する。好ましくは、羊膜を可及的に切除し、胎盤(臍帯を含む)を4〜5等分にカットし、水洗し、ポリエチレンの袋に入れて(乾操を防ぐため)、−10〜−20℃に凍結保存する。凍結期間1ケ月以内には製造工程に入る。
【0016】
製造に際しては、解凍して、好ましくは、脱塩水で洗浄し、胎盤重量の(等量/2倍量)の脱塩水を加えながら、ミンチにかけて切り刻み、好ましくは120℃程度で、15分間程度高圧滅菌してタン白質や細胞外マトリックスの高分子化合物の高次構造を破壊(褐色に変色し、ホモジナイズおよび酵素消化が容易になる)する。生の臍帯や羊膜、隔膜などはホモジナイズされ難い。
【0017】
ホモジナイザーで粥状にし、タン白質分解酵素を加える。耐熱性中性タン白質分解酵素は、プロテアーゼーS、パパインW−40、プロテアーゼーNまたはプロテアーゼーPより選ばれる。これらは、いずれもタン白分解酵素であり、いずれも中性領域で作用し、また耐熱性に優れる。パパインW−40はパパイア果汁の乳汁から抽出されたものである。プロテアーゼーS、パパインW−40、プロテアーゼーNまたはプロテアーゼーPは、いずれも天野エンザイム株式会社より市販されている。この添加量は胎盤の重量の0.05〜0.15%程度が好ましい。また、酵素消化は、プロテアーゼーS、パパインW−40、プロテアーゼーNまたはプロテアーゼーPより選ばれる耐熱性中性タン白質分解酵素を複数種使用すると重複消化が可能となるので好ましい。
【0018】
また、酵素消化を撹拌下、好ましくは温度25〜65℃で行うと、雑菌の混入・増殖を積極的に抑制することが出来るので好ましい。特に、この際、撹拌機付き・恒温ヒーター付きの酵素反応タンクを使用すると雑菌の混入・増殖を積極的に抑制することが出来るので好ましい。タン白質分解酵素を加え、好ましくは攪拌機・恒温ヒーター付酵素反応タンクにて好ましくは、10〜24時間、消化し液状化する。消化液のPHは8.0〜5.0で無調整で行う。
【0019】
酵素消化に於ける温度条件は各酵素特性より好ましくは次を基本として設定する。
・高温耐熱性・中性タン白質分解酵素:プロテアーゼ−Sは、55℃〜65℃
・高温耐熱性・中性タン白質分解酵素:パパイン−W40は、45℃〜50℃
・中温耐熱性・中性タン白質分解酵素:プロテアーゼ−Nは、30℃〜55℃
・低温・中性タン白質分解酵素:プロテアーゼーPは25℃〜45℃
(但し、いずれの酵素も天野エンザイム株式会社製)
【0020】
酵素消化の開始時には、防腐剤を加えることも好ましい。防腐剤としては、ヘキサノール/エタノール混合物(好ましくは1対1)が好ましく挙げられ、その添加量は、好ましくはホモジネイト容積の1〜0.1%の割合に加える。
【0021】
酵素消化の進行と共に過酸化脂質や胎盤臭の成分はヘキサノールと共に垢状に液面に浮上する。浮上する垢状物質をヘキサノール層と一緒に布製の網で潰し取る。更に、好ましくは、へキサノール/エタノール混合液を加え、攪拌し、しばらく放置して同じ操作をもう一度、繰り返す。消化後、布製の網で濃過して羊膜、胎盤隔膜、血管などの未消化の破片を濾し取る。
【0022】
濾液に防腐剤を加えて、高圧滅菌し、放冷し、濃縮した後、凍結乾燥(好ましくは水分3%以下)し、無菌状態で粉砕し、ハードカプセルに詰め、プラセンタエキス粉末製品とする。
【0023】
また、酵素消化終了後の消化液にL−アルギニン、ニンニクエキスなどの栄養素を配合し、高圧滅菌(例えば120℃、15分間)してもよい。
【0024】
【実施例】
本発明を実施例に基づきさらに詳細に説明する。
実施例1
(原料処理工程)
正常分娩ヒトまたはブタより娩出した胎盤を生のまま凍結し、7日〜10日間静置した凍結胎盤および勝帯2,000gは水道水で洗浄、解凍経過中に3〜5cmにカットし、付着している血液、血餅などは棄て、直ちにホモゲナイザーで粥状にした。
【0025】
(原料調整工程(1))
この粥状胎盤を高圧滅菌器で殺菌(120℃、10〜15分間)し、放冷(室温)し、遊離した液体部分に植物性、耐熱性タン白質分解酵素パパインW−40(2.0グラム)を溶かし、再度ホモゲナイザーで均一化し、2,000gの調整原料(1)を得た。
【0026】
(酵素消化工程・調整工程・原料(2))
調整原料(1)を攪拌機・恒温ヒーター付酵素反応タンクに注入し、10N苛性ソーダーにて水素イオン濃度PH7.0に調整し、ヘキサノール0.1m1を加え、50℃〜55℃の恒温条件で20時間、調整原料(1)の酵素消化を行った。消化液には防腐剤(パラべン)2gを加え、高圧滅菌器で殺菌(120℃、10〜15分間)し、放冷(室温)の後、濾布にて濾過し、一部の沈殿物を除き、1,900gの調整原料(2)を得た。
【0027】
(凍結乾燥工程)
調整原料(2)を濃縮エキス分15%まで濃縮し、凍結乾燥(水分3%以下)し、無菌状態で粉砕し、ハードカプセルに詰めプラセンタエキス製品を得た。
実施例1により得たプラセンタエキスの製造実験成績は表1の如くである。
【0028】
【表1】

Figure 2004097033
【0029】
上記とパパイン−W40を、プロテアーゼ−S、プロテアーゼ−N、プロテアーゼ−Pに変えた以外は同様にし、以下の成分調整工程によりプラセンタエキスを製造した。
【0030】
(成分調整工程)
調整原料(2)は常温にて0.45〜0.20μmセルロースアセテイトメンブランフィルターで濾過し、バラペン0.2%含有無菌水で成分量を調整し、1,874g〜1,906g(約1,874ml〜1,906ml)のプラセンタエキス液状製品を得た。
表2は、実施例1で得られたプラセンタエキス製品試験成績である。
【0031】
【表2】
Figure 2004097033
【0032】
プロテアーゼーNにより製造したプラセンタエキス液状製品の性質は次の如くであった。
Figure 2004097033
【0033】
また、凍結乾燥により製造したプラセンタエキス粉末の製品試験成績は次の如くである。
Figure 2004097033
【0034】
実施例2
実施例1より、プロテアーゼ−N使用による収量ならびに窒素含量が良好であることがわかったので、製造量をスケールアップした状態で再テストした。
(原料処理工程)
正常分娩ヒトまたはブタより娩出した胎盤を生のまま凍結し、7日間静置した凍結胎盤および臍帯10,000gは水道水で洗浄、解凍経過中に3〜5cmにカットし付着している血液、血餅などは棄て、直ちにホモゲナイザーで粥状にし、3℃、5日間冷蔵庫に保存した。
【0035】
(原料調整工程・調整原料(1))
粥状胎盤は高圧滅菌器で殺菌(120℃、10〜15分間)し、放冷(室温)し、遊離した液体部分に中性タン白質分解酵素プロテアーゼーN 2.5gを溶解し、元に戻し、再度ホモゲナイザーで均一化し、10,000gの調整原料(1)を得た。
【0036】
(酵素消化工程・調整原料(2))
調整原料(1)は、攪拌機・恒温ヒーター付き酵素反応タンクに注入し、10N苛性ソーダーにて水素イオン濃度pH7.0に調整、へキサノール0.5mlを加え、55℃の恒温条件で20時間、調整原料(1)の酵素消化を行った。
消化液には防腐剤(パラペン)10gを加え、高圧滅菌器で殺菌(120℃、10〜15分間)し、放冷(室温)の後、ヤシガラ炭100gを加え、遠心分離器により不溶沈殿物を除き同時に脱色し、9,500gの調整原料(2)を得た。
【0037】
(成分調整工程)
調整原料(2)は常温にて、0.45μmセルロースアセテイトメンブランフィルターで濾過し、さらに0.20μmセルロ←スアセテイトメンブランフィルターで濾過し、バラペン0.2%含有無菌水で成分量を調整し、9,500g(約9,500ml)のプラセンタエキス液状製品を得た。
実施例2により得たプラセンタエキスの製品試験成績は表3の如くである。
【0038】
【表3】
Figure 2004097033
【0039】
またプラセンタエキスの性状は実施例1のプロテアーゼ−Nにより製造したプラセンタエキスの性状の範囲内であった。
【0040】
実施例3
(2種類の酵素で重複消化法での製造例)
(原料処理工程)
正常分娩ヒトまたはブタより娩出した胎盤を生のまま凍結し、7日間静置した凍結胎盤および臍帯2,000gは水道水で洗浄、解凍経過中に3〜5cmにカットし、付着している血液、血餅などは棄て、直ちにホモゲナイザーで粥状にし、3℃、5日間冷蔵庫に保存した。
【0041】
(原料調整工程・調整原料(1))
粥状胎鮭は高圧滅菌器で殺菌(120℃、10〜15分間)後、放冷し、遊離した液体部分に中性タン白質分解酵素はプロテアーゼーS、パパインーW40、プロテアーゼーN、プロテアーゼーPのいずれの場合も、0.5gを溶解し、元に戻し、再度ホモゲナイザーで均一化し、2,000gの調整原料(1)を得た。
【0042】
(酵素消化工程A・調整原料(2))
調整原料(1)は、攪拌機・恒温ヒーター付き酵素反応タンクに注入し、10N苛性ソーダーにて水素イオン濃度pH7.0に調整、へキサノール0.1mlを加え、25〜65℃恒温朱件で10時間、調整原料(1)の酵素消化を行って、調整原料(2)を得た。
【0043】
(酵素消化工程B・調整原料(3))
酵素消化した調整原料(2)に、中性タン白質分解酵素を表4に記載した組み合わせで各酵素0.5gを一部の調整原料(2)に溶解し、元に戻し、十分攪拌の後、重複酵素消化を行った。
【0044】
【表4】
Figure 2004097033
【0045】
重複酵素消化は攪拌機・恒温ヒーター付き酵素反応タンクの適正反応温度を設定し、追加10時間、調整原料(2)の酵素消化を行った。
消化終了液には防腐剤(バラペン)2.0gを加え、高圧滅菌器で殺菌(120℃、1.0〜15分間)し、放冷(室温)の後、ヤシガラ炭(20g)を加え、遠心分離器により不溶沈殿物を除き同時に脱色し、2,000gの調整原料(3)を得た。
【0046】
(成分調整工程)
調整原料(3)は常温にて、ポアサイズ0.45μmセルロースアセテイトメンブランフィルターで濾過し、さらにポアサイズ0.20μmセルロースアセテイトメンブランフィルターで濾過し、パラペン0.2%含有無菌水で成分量を調整し、約1,820g〜1,900g(約1,820ml〜1,900ml)のプラセンタエキス液状製品を得た。
【0047】
実施例3により得たプラセンタエキスの製造実験成績は表5の如くである。
但し、酵素組合せNoは表4による。
【0048】
【表5】
Figure 2004097033
【0049】
【発明の効果】
本発明によるプラセンタエキスは満期正常分娩のヒトまたはブタ胎盤を中性タン白質分解酵素による消化で液状化し加熱滅菌して調整したものであるので、酵素消化を受けたタン白質や加水分解された栄養成分と栄養芽細胞が作り出した栄養因子を100%抽出したエキスである。
【0050】
本発明の製造方法は、酵素消化過程に於けるPH調節等の作業の繁雑さを簡素化できる。また、攪拌・恒温ヒーター付き酵素反応タンクの使用により、耐熱性中性タン白質分解酵素による消化が容易にできるのみならず、任意の反応条件の中性タン白質分解酵素の選択、複数の中性タン白質分解酵素による重複消化が可能となり、この事により雑菌の混入・増殖を積極的に抑制することができる。したがって、高収量の有効成分の抽出が低コストで行うことができる。
【0051】
また、本発明によるプラセンタエキス粉末は医薬品として投与することが出来るだけでなく、種々の形態,例えば栄養補助食品(飲料も含む)の形で与えることも可能である。[0001]
[Industrial applications]
The present invention relates to a method for producing a placenta extract, and more particularly, to a method for producing a placenta extract by digestion of a heat-resistant neutral proteinase of a normal placenta of human or pig.
[0002]
[Prior art]
In general, the physiology of the mammalian placenta is the supply and nutrition of oxygen for fetal development in the mother. The maternal and fetal circulatory systems are completely separated through a trophoblast layer. In the past decade, nutritional factors such as nerve growth factor and hepatocyte growth factor have attracted attention in the medical field, and it has been found that most of these known trophic factors are produced in placental trophoblasts.
[0003]
Placenta extract is extracted to contain all the components contained in the placental tissue, and its biological activity is not due to a single substance, but various components act variously, and the connective tissue growth action, In addition to aging and anti-chronic ulcer effects, medical effects on diseases mainly involving neurological symptoms, gynecological diseases, dermatological diseases and the like have already been clarified by injections of human placenta extract. In recent years, it has been revealed that a number of trophic factors produced by placental trophoblasts are central to these biological activities.
[0004]
Desirable active ingredients of placenta extract include nucleotide nucleoside,
Of interest are free arginine and peptides containing arginine, intermediate metabolites of steroid hormones, especially C-21 steroids and C-19 steroids, mucopolysaccharides (hyaluronic acid, chondroitin sulfate), inositol and inositol phospholipids.
[0005]
In Japan, there are two types of placenta extract for administration: a hydrolyzed solution of human placenta at normal term delivery with hydrochloric acid, and a drug name "Laennec", which is a mixture of a pepsin digestive solution and a hydrolyzed solution of hydrochloric acid as a residue. Both manufacturing methods were developed in the 1950s and 1960s, and "Laennec" was approved for manufacture in 1958 for the indication "cirrhosis" from the Ministry of Health and Welfare (Ministry of Health, Labor and Welfare). Improvement of liver function in chronic liver disease "has been announced.
[0006]
Specifically, the placenta extract is usually manufactured by the following procedure.
First, a normal placenta of human or pig is refrigerated at 2 to 4 ° C. for about 4 days, washed, pulverized, homogenized by adding acetone, defatted, and dried. The dried product is acidified with hydrochloric acid (pH 2.0), digested with pepsin all day and night, and centrifuged to collect the digested liquid. The precipitate is hydrolyzed by adding hydrochloric acid (5N) and heating. The hydrolyzed solution is decolorized with activated charcoal, filtered, mixed with pepsin digestion solution, hydrochloric acid is removed as much as possible with an anion exchange resin, and the pH is corrected to 6.1 to 6.4 using caustic soda, and the placenta extract is extracted. And
[0007]
The placenta extract exhibits a purple color in the ninhydrin test solution and a red-purple to blue-violet color in the burette reaction. The relative content of the active ingredient is determined by a nitrogen determination method (Kjeldahl method) to be 0.30 to 0.35 w / v%, and the residue on ignition is 1.0% or less.
[0008]
In another method, the quarantined three-month-old healthy pigs' fresh placenta are repeatedly frozen and immersed at low temperatures without heat treatment or chemical treatment, crushing cell tissues, and extracting the protoplasma. Then, it is prepared by removing protein and ultra-leakage to obtain a placenta liquid. This placenta liquid has an alkaline phosphatase content of 1.00 King Armstrong units per 100 ml. (The titer of alkaline phosphatase is 1 King Armstrong unit (1 KAU) when 1 mg of phenol is liberated in 15 minutes in the enzymatic reaction per 100 ml of the solution containing alkaline phosphatase.)
[0009]
Placenta liquid is purple in ninhydrin TS and red-purple to blue-violet in Buret reaction. The relative content of the active ingredient is determined by a nitrogen determination method (Kjeldahl method) to be 0.30 to 0.35 w / v%, and the residue on ignition is 1.0% or less.
[0010]
However, in the case of heat hydrolysis with hydrochloric acid, nucleosides and nucleosides are hydrolyzed to nucleobases, and the constituent sugars of mucopolysaccharides, inositol phospholipids, etc. are almost completely decomposed, and a large amount of black-brown substances are produced, and nutrient factors are produced. Mimics impairment. Further, removal of the coloring substance requires decolorization with activated carbon, which is extremely complicated.
[0011]
Most of the trophic factors are degraded by pepsin digestion at 37 ° C. with hydrochloric acid (pH 2.0). However, in any of the production methods, since hydrochloric acid is used, it is necessary to remove hydrochloric acid as much as possible with an anion exchange resin and to appropriately neutralize PH with a caustic soda solution. Furthermore, activated carbon is used to remove lipid peroxide and placental odor contained in a relatively large amount in the placenta, but it is insufficient and plays a major role in the loss of effective nutritional factors.
[0012]
[Problems to be solved by the invention]
Placenta extract that eliminates the complexity of processing, such as adjustment of the proper action pH in the enzymatic digestion process as in the conventional extraction method as described above, removal of hydrochloric acid after completion of digestion, and final correction of PH as a placenta extract There has been a demand for a method for producing the same.
[0013]
[Means for Solving the Problems]
The present inventors, by using a specific heat-resistant neutral proteinase, the complexity of the enzymatic digestion process, that is, the adjustment of the proper action PH in the enzymatic digestion kneading, hydrochloric acid after the completion of digestion. It has been found that the complexity of processing such as removal and final correction of PH as a placenta extract can be simplified, and effective digestion can be performed.
[0014]
The present invention provides a placenta extract, wherein a normal parturition human or porcine placenta is enzymatically digested using a heat-resistant neutral proteinase selected from protease S, papain W-40, protease N or protease P. Manufacturing method,
Also, at this time, a method for producing a placenta extract, comprising performing enzyme digestion using a plurality of heat-resistant neutral proteinases selected from protease S, papain W-40, protease N or protease P. Yes,
Further, there is provided a method for producing a placenta extract, wherein the enzyme digestion is carried out at a temperature of 25 to 65 ° C. with stirring.
[0015]
BEST MODE FOR CARRYING OUT THE INVENTION
The placenta from normal human or pig labor is used. The placenta is usually associated with degenerative changes such as degeneration, apoptosis, and necrosis, and thoroughly removes syneresis and dark brown clots, including blood, while washing with tap water. Preferably, the amniotic membrane is removed as much as possible, the placenta (including the umbilical cord) is cut into 4-5 equal parts, washed with water, placed in a polyethylene bag (to prevent drying), and Store frozen at ℃. The manufacturing process starts within one month of freezing.
[0016]
In the production, it is thawed, preferably washed with demineralized water, minced with minced water while adding demineralized water (equal volume / double volume) of the placenta weight, preferably at about 120 ° C. and high pressure for about 15 minutes. Sterilize to destroy higher order structures of protein and macromolecular compounds of extracellular matrix (discolor brown, facilitating homogenization and enzymatic digestion). Raw umbilical cord, amniotic membrane, diaphragm, etc. are difficult to homogenize.
[0017]
Pour the mixture with a homogenizer and add proteinase. The thermostable neutral proteinase is selected from protease S, papain W-40, protease N or protease P. These are all proteolytic enzymes, all of which act in the neutral region and have excellent heat resistance. Papain W-40 is extracted from the milk of papaya juice. Protease S, papain W-40, protease N or protease P are all commercially available from Amano Enzyme Co., Ltd. This amount is preferably about 0.05 to 0.15% of the weight of the placenta. Enzymatic digestion is preferably performed by using a plurality of heat-resistant neutral proteolytic enzymes selected from protease S, papain W-40, protease N or protease P since double digestion becomes possible.
[0018]
In addition, it is preferable to perform the enzymatic digestion with stirring, preferably at a temperature of 25 to 65 ° C., because it is possible to positively suppress the contamination and growth of various bacteria. In particular, in this case, it is preferable to use an enzyme reaction tank equipped with a stirrer and a constant temperature heater, since it is possible to positively suppress the contamination and growth of various bacteria. The proteinase is added, and the mixture is digested and liquefied preferably for 10 to 24 hours in an enzyme reaction tank equipped with a stirrer and a constant temperature heater. The pH of the digestive juice is 8.0 to 5.0 without any adjustment.
[0019]
The temperature conditions in the enzymatic digestion are preferably set based on the following, more preferably from the characteristics of each enzyme.
-High temperature heat resistance-Neutral protein degrading enzyme: Protease-S is 55C to 65C
・ High temperature heat resistance ・ Neutral proteinase: Papain-W40 is 45 ° C to 50 ° C
-Medium temperature heat resistance-Neutral proteinase: Protease-N is 30C to 55C
・ Low temperature / neutral proteinase: 25 ° C to 45 ° C for protease P
(However, all enzymes are manufactured by Amano Enzyme Co., Ltd.)
[0020]
It is also preferred to add a preservative at the start of the enzymatic digestion. As the preservative, a hexanol / ethanol mixture (preferably 1: 1) is preferably mentioned, and the amount of the preservative added is preferably 1 to 0.1% of the homogenate volume.
[0021]
As the enzymatic digestion progresses, the lipid peroxide and the placental odor components float on the liquid surface together with hexanol. The floating debris is crushed together with the hexanol layer with a cloth net. Further, preferably, a hexanol / ethanol mixture is added, stirred, left for a while, and the same operation is repeated once again. After digestion, the mixture is concentrated with a cloth mesh, and undigested fragments such as amniotic membrane, placental septum and blood vessels are filtered off.
[0022]
A preservative is added to the filtrate, which is then sterilized under high pressure, allowed to cool, concentrated, freeze-dried (preferably, 3% or less in water content), pulverized in an aseptic state, and packed in a hard capsule to obtain a placenta extract powder product.
[0023]
Alternatively, nutrients such as L-arginine, garlic extract and the like may be added to the digestion fluid after completion of enzyme digestion, and the mixture may be subjected to high-pressure sterilization (for example, at 120 ° C. for 15 minutes).
[0024]
【Example】
The present invention will be described in more detail based on examples.
Example 1
(Raw material processing step)
A placenta delivered from a normal parturition human or pig is frozen as it is, and the frozen placenta and 2,000 g of frozen placenta that have been allowed to stand for 7 to 10 days are washed with tap water, cut to 3 to 5 cm during thawing, and adhered. Blood and blood clots were discarded and immediately porridge with a homogenizer.
[0025]
(Raw material adjustment process (1))
The porcelain placenta was sterilized in a high-pressure sterilizer (120 ° C., 10 to 15 minutes), allowed to cool (room temperature), and the released liquid portion was plant and heat-resistant proteinase papain W-40 (2.0). G) was dissolved and homogenized again with a homogenizer to obtain 2,000 g of an adjusted raw material (1).
[0026]
(Enzyme digestion process / adjustment process / raw material (2))
The adjusted raw material (1) was poured into an enzymatic reaction tank equipped with a stirrer and a constant temperature heater, adjusted to a hydrogen ion concentration of pH 7.0 with 10N caustic soda, added with 0.1 ml of hexanol, and added at a constant temperature of 50 to 55 ° C. The enzymatic digestion of the adjusted raw material (1) was performed for a time. To the digestive juice, 2 g of preservative (paraben) was added, sterilized in a high-pressure sterilizer (120 ° C., 10 to 15 minutes), allowed to cool (room temperature), filtered through a filter cloth, and partially precipitated. Excluding the materials, 1,900 g of the adjusted raw material (2) was obtained.
[0027]
(Freeze-drying process)
The adjusted raw material (2) was concentrated to a concentrated extract content of 15%, freeze-dried (water content of 3% or less), pulverized in an aseptic state, and packed in hard capsules to obtain a placenta extract product.
Table 1 shows the experimental results of the production of the placenta extract obtained in Example 1.
[0028]
[Table 1]
Figure 2004097033
[0029]
A placenta extract was produced in the same manner as described above except that papain-W40 was changed to protease-S, protease-N, and protease-P.
[0030]
(Component adjustment step)
The adjusted raw material (2) was filtered at room temperature through a 0.45 to 0.20 μm cellulose acetate membrane filter, and the amount of components was adjusted with sterile water containing 0.2% of balapene to obtain 1,874 g to 1,906 g (about 1 , 874 ml to 1,906 ml).
Table 2 shows the placenta extract product test results obtained in Example 1.
[0031]
[Table 2]
Figure 2004097033
[0032]
The properties of the placenta extract liquid product produced with Protease N were as follows.
Figure 2004097033
[0033]
The product test results of the placenta extract powder produced by freeze-drying are as follows.
Figure 2004097033
[0034]
Example 2
From Example 1, it was found that the yield and the nitrogen content by using protease-N were good, so that the production was scaled up and retested.
(Raw material processing step)
A placenta delivered from a normal parturition human or pig is frozen as it is, and the frozen placenta and umbilical cord 10,000 g left standing for 7 days are washed with tap water and cut to 3-5 cm during the course of thawing. Blood clots and the like were discarded and immediately made into a porridge with a homogenizer and stored in a refrigerator at 3 ° C. for 5 days.
[0035]
(Raw material adjustment process / adjusted raw material (1))
The porcine placenta is sterilized in a high-pressure sterilizer (120 ° C., 10 to 15 minutes), allowed to cool (room temperature), and dissolved 2.5 g of neutral proteinase protease N in the liberated liquid part. Then, the mixture was homogenized again with a homogenizer to obtain 10,000 g of an adjusted raw material (1).
[0036]
(Enzyme digestion process / adjusted raw material (2))
The adjusted raw material (1) was poured into an enzyme reaction tank equipped with a stirrer and a constant temperature heater, adjusted to a hydrogen ion concentration of pH 7.0 with 10 N caustic soda, and 0.5 ml of hexanol was added. The adjusted raw material (1) was subjected to enzymatic digestion.
10 g of preservative (parapen) is added to the digested liquid, sterilized by a high-pressure sterilizer (120 ° C., 10 to 15 minutes), allowed to cool (room temperature), 100 g of coconut shell charcoal is added, and the insoluble precipitate is centrifuged. , And 9,500 g of an adjusted raw material (2) was obtained.
[0037]
(Component adjustment step)
The adjusted raw material (2) was filtered at room temperature through a 0.45 μm cellulose acetate membrane filter, further filtered through a 0.20 μm cellulo ← acetate membrane filter, and the component amount was adjusted with 0.2% balpen in sterile water. Then, 9,500 g (about 9,500 ml) of a placenta extract liquid product was obtained.
The product test results of the placenta extract obtained in Example 2 are as shown in Table 3.
[0038]
[Table 3]
Figure 2004097033
[0039]
The properties of the placenta extract were within the range of the properties of the placenta extract produced using the protease-N of Example 1.
[0040]
Example 3
(Example of production by double digestion with two enzymes)
(Raw material processing step)
A placenta delivered from a normal parturition human or pig is frozen as it is, and the frozen placenta and 2,000 g of umbilical cord which have been allowed to stand for 7 days are washed with tap water, cut to 3 to 5 cm during the course of thawing, and blood adhered. The blood clot was discarded, and the mixture was immediately porridged with a homogenizer and stored in a refrigerator at 3 ° C. for 5 days.
[0041]
(Raw material adjustment process / adjusted raw material (1))
The porridge salmon is sterilized in a high-pressure sterilizer (120 ° C., 10 to 15 minutes) and allowed to cool, and the neutralized proteinase in the released liquid portion is any of protease S, papain-W40, protease N, and protease P. In the case of the above, 0.5 g was dissolved, returned, and homogenized again with a homogenizer to obtain 2,000 g of the adjusted raw material (1).
[0042]
(Enzyme digestion step A / adjusted raw material (2))
The adjusted raw material (1) was poured into an enzyme reaction tank equipped with a stirrer and a constant temperature heater, adjusted to a hydrogen ion concentration of pH 7.0 with 10N caustic soda, and 0.1 ml of hexanol was added. Enzymatic digestion of the adjusted material (1) was performed for a time to obtain an adjusted material (2).
[0043]
(Enzyme digestion step B / adjusted raw material (3))
0.5 g of each enzyme is dissolved in a part of the adjustment raw material (2) in the combination shown in Table 4 with the neutral protein degrading enzyme in the enzyme digested adjustment raw material (2), and the solution is returned to the original state. , And double enzyme digestion was performed.
[0044]
[Table 4]
Figure 2004097033
[0045]
For the duplicate enzyme digestion, the appropriate reaction temperature of an enzyme reaction tank equipped with a stirrer and a constant temperature heater was set, and the enzyme digestion of the adjusted raw material (2) was performed for an additional 10 hours.
To the digestion end solution was added 2.0 g of a preservative (barapen), sterilized in a high-pressure sterilizer (120 ° C., 1.0 to 15 minutes), allowed to cool (room temperature), and added coconut charcoal (20 g). Insoluble precipitates were removed by a centrifugal separator and decolored at the same time to obtain 2,000 g of a raw material (3).
[0046]
(Component adjustment step)
The adjusted raw material (3) was filtered at room temperature through a 0.45 μm pore size cellulose acetate membrane filter, further filtered through a 0.20 μm pore size cellulose acetate membrane filter, and the amount of components was adjusted with sterile water containing 0.2% parapen. Then, about 1,820 g to 1,900 g (about 1,820 ml to 1,900 ml) of a placenta extract liquid product was obtained.
[0047]
Table 5 shows the production test results of the placenta extract obtained in Example 3.
However, the enzyme combination No. is shown in Table 4.
[0048]
[Table 5]
Figure 2004097033
[0049]
【The invention's effect】
The placenta extract according to the present invention is prepared by liquefaction and heat sterilization of human or porcine placenta of normal term labor and digestion by neutral proteinase, so that the protein digested by enzyme and hydrolyzed nutrients It is an extract obtained by extracting 100% of nutrients produced by the components and trophoblasts.
[0050]
The production method of the present invention can simplify the complexity of operations such as pH adjustment in the enzymatic digestion process. In addition, the use of an enzyme reaction tank with a stirring and constant temperature heater not only facilitates digestion with heat-resistant neutral proteinases, but also allows the selection of neutral proteinases under any reaction conditions, The double digestion by the proteinase can be carried out, whereby the contamination and growth of various bacteria can be positively suppressed. Therefore, high-yield extraction of the active ingredient can be performed at low cost.
[0051]
In addition, the placenta extract powder according to the present invention can be administered not only as a pharmaceutical, but also in various forms, for example, in the form of dietary supplements (including beverages).

Claims (3)

正常分娩ヒトまたはブタ胎盤を、プロテアーゼーS、パパインW−40、プロテアーゼーNまたはプロテアーゼーPより選ばれる耐熱性中性タン白質分解酵素を使用して酵素消化することを特徴とするプラセンタエキスの製造方法。A method for producing a placenta extract, comprising enzymatically digesting a normal parturition human or porcine placenta with a heat-resistant neutral proteinase selected from protease S, papain W-40, protease N or protease P. プロテアーゼーS、パパインW−40、プロテアーゼーNまたはプロテアーゼーPより選ばれる複数種のタン白質分解酵素を使用して酵素消化することを特徴とする請求項1に記載のプラセンタエキスの製造方法。The method for producing a placenta extract according to claim 1, wherein the enzyme digestion is performed using a plurality of types of proteinases selected from protease S, papain W-40, protease N, and protease P. 酵素消化を撹拌下、温度25〜65℃で行うことを特徴とする請求項1に記載のプラセンタエキスの製造方法。The method for producing a placenta extract according to claim 1, wherein the enzymatic digestion is performed at a temperature of 25 to 65 ° C with stirring.
JP2002260495A 2002-09-05 2002-09-05 Method for producing placental extract Pending JP2004097033A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002260495A JP2004097033A (en) 2002-09-05 2002-09-05 Method for producing placental extract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002260495A JP2004097033A (en) 2002-09-05 2002-09-05 Method for producing placental extract

Publications (1)

Publication Number Publication Date
JP2004097033A true JP2004097033A (en) 2004-04-02

Family

ID=32261196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002260495A Pending JP2004097033A (en) 2002-09-05 2002-09-05 Method for producing placental extract

Country Status (1)

Country Link
JP (1) JP2004097033A (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006158214A (en) * 2004-12-02 2006-06-22 Happy Shoji Kk Placental extract powder-formulated food
JP2006304784A (en) * 2005-03-31 2006-11-09 Nippon Seibutsu Seizai:Kk Method for differentiating and inducting bone marrow cell
KR100901138B1 (en) 2008-03-18 2009-06-09 재단법인서울대학교산학협력재단 Method of extracting porcine placenta and health food comprising the extract
KR100932183B1 (en) 2008-10-22 2009-12-16 주식회사 한국천연물사이언스 Extraction Method of Horse Placenta and Food Composition Using the Same
JP2010030946A (en) * 2008-07-29 2010-02-12 Asuka Corporation:Kk Whitening cosmetic
KR101035094B1 (en) * 2008-06-24 2011-05-19 주식회사 보고신약 A method of preparing placental extract
WO2012157734A1 (en) * 2011-05-18 2012-11-22 株式会社ニチレイバイオサイエンス Wrinkle-improving composition containing placenta-derived component
JP2013048564A (en) * 2011-08-30 2013-03-14 Leda Co Ltd Method for extracting placenta extract and nutrient supplement
JP2017100998A (en) * 2015-12-02 2017-06-08 イビデン株式会社 Placenta extract and method for producing placenta extract
JP2017226606A (en) * 2016-06-21 2017-12-28 持田 騎一郎 Composition, agent, cosmetic product or health food
JP6373444B1 (en) * 2017-05-10 2018-08-15 株式会社ホルス Amnion-derived raw material manufacturing method, cosmetic manufacturing method, and health food manufacturing method
WO2018199231A1 (en) * 2017-04-28 2018-11-01 一丸ファルコス株式会社 Placenta extract

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006158214A (en) * 2004-12-02 2006-06-22 Happy Shoji Kk Placental extract powder-formulated food
JP2006304784A (en) * 2005-03-31 2006-11-09 Nippon Seibutsu Seizai:Kk Method for differentiating and inducting bone marrow cell
KR100901138B1 (en) 2008-03-18 2009-06-09 재단법인서울대학교산학협력재단 Method of extracting porcine placenta and health food comprising the extract
KR101035094B1 (en) * 2008-06-24 2011-05-19 주식회사 보고신약 A method of preparing placental extract
JP2010030946A (en) * 2008-07-29 2010-02-12 Asuka Corporation:Kk Whitening cosmetic
KR100932183B1 (en) 2008-10-22 2009-12-16 주식회사 한국천연물사이언스 Extraction Method of Horse Placenta and Food Composition Using the Same
JP6117456B1 (en) * 2011-05-18 2017-04-19 株式会社ニチレイバイオサイエンス Wrinkle improving composition containing placenta-derived component
JPWO2012157734A1 (en) * 2011-05-18 2014-07-31 株式会社ニチレイバイオサイエンス Wrinkle improving composition containing placenta-derived component
JP5932783B2 (en) * 2011-05-18 2016-06-08 株式会社ニチレイバイオサイエンス Wrinkle improving composition containing placenta-derived component
WO2012157734A1 (en) * 2011-05-18 2012-11-22 株式会社ニチレイバイオサイエンス Wrinkle-improving composition containing placenta-derived component
JP2017114868A (en) * 2011-05-18 2017-06-29 株式会社ニチレイバイオサイエンス Compositions for wrinkle improvement containing placenta-derived component
JP2013048564A (en) * 2011-08-30 2013-03-14 Leda Co Ltd Method for extracting placenta extract and nutrient supplement
JP2017100998A (en) * 2015-12-02 2017-06-08 イビデン株式会社 Placenta extract and method for producing placenta extract
JP2017226606A (en) * 2016-06-21 2017-12-28 持田 騎一郎 Composition, agent, cosmetic product or health food
WO2018199231A1 (en) * 2017-04-28 2018-11-01 一丸ファルコス株式会社 Placenta extract
JP6373444B1 (en) * 2017-05-10 2018-08-15 株式会社ホルス Amnion-derived raw material manufacturing method, cosmetic manufacturing method, and health food manufacturing method
WO2018207810A1 (en) * 2017-05-10 2018-11-15 株式会社ホルス Method for producing amnion-derived raw material, method for producing cosmetic, and method for producing health food
JP2018188401A (en) * 2017-05-10 2018-11-29 株式会社ホルス Method for producing amniotic membrane-derived raw material, method for producing cosmetic product, and method for producing health food
KR20190005926A (en) 2017-05-10 2019-01-16 가부시키가이샤 호루스 Method for manufacturing amniotic membrane-derived raw material, manufacturing method of cosmetics and manufacturing method for health food
CN109247011A (en) * 2017-05-10 2019-01-18 荷鲁斯股份有限公司 The manufacturing method of the manufacturing method of raw material from amnion, the manufacturing method of cosmetics and healthy food
RU2733542C1 (en) * 2017-05-10 2020-10-05 Хорус Ко., Лтд. Methods for producing raw material from amniotic membrane, method for producing cosmetic agent and method for producing healthy food products
CN109247011B (en) * 2017-05-10 2021-11-23 荷鲁斯股份有限公司 Method for producing amnion-derived material and method for producing health food

Similar Documents

Publication Publication Date Title
CN111670997B (en) Preparation method of immunity-enhancing compound protein peptide enzymatic hydrolysate, immunity-enhancing compound protein peptide beverage and preparation method thereof
JP2004097033A (en) Method for producing placental extract
US10398162B2 (en) Method for manufacturing aloe extract, and aloe extract
CN108432883A (en) A kind of momordica grosvenori gingkgo soymilk and preparation method thereof
CN110881666A (en) Small molecule compound peptide preparation for special nutritional physique of astronaut
CN102511561A (en) Production method of sugar-free soymilk
JP2007029090A (en) Method for producing low-degeneration defatted rice bran
CN106360718A (en) Extraction technology of aloe vera gels
JP2008056645A (en) Anti-oxidant peptide obtained by reaction of protein in enzymatically treated royal jelly with polypeptide and method for producing the same
CN102987275B (en) A kind of preparation method of the soy oligosaccharides glycopeptide of high biological value
CN107114793A (en) It is a kind of to comprehensively utilize the method that sturgeon bone prepares calcium and chondroitin sulfate
CN111802653A (en) Tuna oligopeptide powder composition and preparation method and application thereof
CN102550689A (en) Production method of sugar-free sweet soybean milk
KR20040055931A (en) Manufa cture method of collagen and manufactures using thereof
JP5794678B2 (en) Glucagon-like peptide-1 secretion promoter
CN101480491B (en) Bone collagen polypeptide composite solution for regulating intestines and preparation method thereof
JP2006158214A (en) Placental extract powder-formulated food
CN109452654A (en) A kind of formula food and preparation method thereof for treating diabetes
Baker et al. Valorisation of waste olive pomace: Laboratory and pilot scale processing to extract dietary fibre
CN107595924A (en) A kind of bone-melon extract injection preparation and corresponding pharmaceutical composition
US5707657A (en) Food supplement containing animal fetal mesenchymal matter and animal fetal organ extracts
Nothnagel Encyclopedia of Practical Medicine
JP2006149290A (en) Food mixed with placenta powder
CN106722976A (en) There are the health products of alleviation and therapeutic action to gout
JP4869492B2 (en) Anti-tumor composition

Legal Events

Date Code Title Description
A621 Written request for application examination

Effective date: 20040601

Free format text: JAPANESE INTERMEDIATE CODE: A621

A131 Notification of reasons for refusal

Effective date: 20070814

Free format text: JAPANESE INTERMEDIATE CODE: A131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071225